Bio-Techne Corporation (NASDAQ:TECH) saw its stock climb 1.9% in premarket trading Monday following a report that activist investor Ananym Capital Management has taken a stake in the Minneapolis-based life sciences tools maker and urged the company to initiate a strategic review that may encompass a sale.
In a letter sent to Bio-Techne's board, Ananym argued that the company has trailed its industry peers and the broader market, and that a transaction with a larger industry buyer could yield greater value for shareholders than remaining independent.
The activist included a pointed assessment of the company's recent performance. "While we are a new investor, shareholders have suffered for years as the company has continued to destroy value," the letter said. "A failure to act now risks further value destruction and even permanent capital impairment, which the board has a duty to avoid by exploring all potential paths to preserving and enhancing value."
Bio-Techne produces instruments and reagents for life-science research, diagnostics and bioprocessing. The company's shares have declined by more than 8% year-to-date, placing its market capitalization at approximately $8.45 billion.
According to the letter, Ananym recognizes the firm's strengths - describing Bio-Techne as owning high-quality assets and maintaining strong customer relationships - but contends that its organic growth has lagged peers. The activist further asserted that investments into adjacent areas have eroded operating margins without producing commensurate growth.
Ananym's assessment said a larger acquirer could achieve cost, revenue and platform synergies that Bio-Techne cannot realize as a standalone company. That argument underpins the activist's push for the board to evaluate sale options alongside other strategic alternatives.
New York-based Ananym Capital Management was founded in 2024 by Chief Investment Officer Alex Silver and Head of Engagement Charlie Penner. The firm manages about $350 million in assets, and its stake in Bio-Techne represents one of its largest positions.
The development adds an M&A-oriented dynamic to the company's outlook and has prompted investors to reassess near-term prospects. The activist's public letter and the subsequent market move underscore the pressure on management and the board to demonstrate how they will drive improved growth and margin performance.
For now, the board's response and any resulting strategic review remain to be seen. The firm's assets and client relationships are cited as strengths in the letter, but the activist's critique centers on execution and the potential upside of combining Bio-Techne with a larger industry player.